Uganda starts Phase I trial of Oxford-developed Ebola vaccine
The first five volunteers have joined the early-stage study, which is testing the candidate vaccine's safety.
By Standard Topic. AI-generated from the reporting listed under Coverage. Published . Updated .
This story is no longer being updated. It reflects reporting up to .
What happened
Uganda has started a Phase I clinical trial of a vaccine developed at Oxford against the Bundibugyo strain of Ebola. The first five volunteers have been enrolled in the study.
Why it matters
The early-stage study is designed to assess the vaccine's safety.
Timeline
- Oct 16, 7:10 AM ET: The Oxford-developed vaccine against Bundibugyo virus disease entered a Phase I clinical trial in Uganda.
- Oct 18, 3:03 PM ET: Uganda enrolled the first five volunteers in the Phase One trial of the Ebola vaccine candidate.
Coverage
- Uganda begins phase one of Ebola Vaccine clinical trials (ntv.co.ug)
- Oxford-developed Ebola vaccine enters Phase I clinical trial in Uganda (OxStu Science)
- Ebola outbreak spreads in Congo and Kenya as cases climb
- Kenya confirms second Ebola case as Congo outbreak grows
- Ebola cases in DR Congo top 9,000 as Kenya reports second infection
More from Health
- Hackensack Meridian Health and Hunterdon Health agree to merge
- Roche signs $15 billion antibody-drug conjugate deal with Hansoh
- Putin's daughter predicts aging breakthroughs within 10 to 20 years
- Cardiologists urged to prescribe exercise for heart patients
- Pennsylvania measles outbreak tops 1,200 as CDC sends investigator
- AstraZeneca enlists Oracle to apply AI in drug trials